Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
Phase 2
Completed
- Conditions
- Insulin Resistance
- Registration Number
- NCT00162799
- Lead Sponsor
- J. Uriach and Company
- Brief Summary
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.
- Detailed Description
Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled.
Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days placebo, 15 days
Washout period: 30 days
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Ages 35 to 60 years old
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Increase of insulin sensitivity in apparently healthy men and woman evaluate by means of i.v. glucose tolerance test (PTEVGMR).
- Secondary Outcome Measures
Name Time Method Reduction antropometric measures associated with insulin resistance and arterial hypertension.
Trial Locations
- Locations (1)
Unitat de Diabetologia, Endocrinologia y Nutrición Hosp Josep Trueta
🇪🇸Girona, Spain